Találati lista | Tudóstér

001-es BibID:	BIBFORM078121
035-os BibID:	(PMID)30830246
Első szerző:	Kárai Bettina (orvos)
Cím:	A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots / Bettina Kárai, Mira Habók, Gyula Reményi, László Rejtő, Anikó Ujfalusi, János Kappelmayer, Zsuzsanna Hevessy
Dátum:	2019
Megjegyzések:	Acute promyelocytic leukemia (APL) is generally characterized by t(15;17)(q24;q21). In some cases, the classic translocation cannot be identified by conventional methods, since the PML-RARA fusion protein results from complex, variant, or cryptic translocation. The diagnostic algorithm of APL starts with screening methods, such as flow cytometry (FC), followed by fluorescence in situ hybridization or polymerase chain reaction to confirm the diagnosis. Our aim was to develop a novel protocol for analyzing APL samples based on multidimensional dot-plots that can provide comprehensive information about several markers at the same time. The protocol included four optimized multidimensional dot-plots, which were tested by retrospective reanalysis of FC results in APL (n?=?8) and non-APL (n?=?12) acute myeloid leukemia (AML) cases. After predicting the potential position of hypergranular- and microgranular-type aberrant promyelocytes, the percentages of blast populations were examined within the gates in all AML cases. The percentage of blasts in each predefined gate was well above the cut-off value (95%) in APL cases in all tubes. In non-APL AML cases, the percentage of blasts in the same gates never reached the cut-off value in all investigated tubes, and even when it did in a single tube, the pattern was markedly different from that observed in APL cases. In conclusion, multidimensional dot-plots can be used for screening APL even in cryptic APL cases, although reproducibility across several laboratories would require standardization of antibodies and fluorochromes. This easy-to-use and quick method can support the diagnosis of APL and the prompt initiation of the appropriate treatment.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Acute promyelocytic leukemia Cryptic translocation Flow cytometry Multidimensional dot-plot
Megjelenés:	Annals of Hematology. - 98 : 6 (2019), p. 1413-1420. -
További szerzők:	Habók Mira Reményi Gyula (1969-) (belgyógyász, haematológus) Rejtő László (1963-) (belgyógyász, haematológus) Ujfalusi Anikó (1968-) (gyermekorvos, laboratóriumi szakorvos) Kappelmayer János (1960-) (laboratóriumi szakorvos) Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos)
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM102796
035-os BibID:	(Scopus)85134324420 (WOS)000825230100001
Első szerző:	Magyari Ferenc (belgyógyász, hematológus)
Cím:	Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies / Magyari Ferenc, Pinczés László Imre, Páyer Edit, Farkas Katalin, Ujfalusi Szilvia, Diószegi Ágnes, Sik Máté, Simon Zsófia, Nagy Gergely, Hevessy Zsuzsanna, Nagy Béla, Illés Árpád
Dátum:	2022
ISSN:	0939-5555 1432-0584
Megjegyzések:	Patients with hematological malignancies (HMs) are at a higher risk of developing severe form and protracted course of COVID-19 disease. We investigated whether the combination of viral replication inhibition with remdesivir and administration of anti-SARS-CoV-2 immunoglobulins with convalescent plasma (CP) therapy might be sufficient to treat B-cell-depleted patients with COVID-19. We enrolled 20 consecutive patients with various HMs with profound B-cell lymphopenia and COVID-19 pneumonia between December 2020 and May 2021. All patients demonstrated undetectable baseline anti-SARS-CoV-2 immunoglobulin levels before CP. Each patient received at least a complete course of remdesivir and at least one unit of CP. Previous anti-CD20 therapy resulted in a more prolonged SARS-CoV-2 PCR positivity compared to other causes of B-cell lymphopenia (p = 0.004). Timing of CP therapy showed a significant impact on the clinical outcome. Simultaneous use of remdesivir and CP reduced time period for oxygen weaning after diagnosis (p = 0.017), length of hospital stay (p = 0.007), and PCR positivity (p = 0.012) compared to patients who received remdesivir and CP consecutively. In addition, time from the diagnosis to CP therapy affected the length of oxygen dependency (p < 0.001) and hospital stay (p < 0.0001). In those cases where there were at least 10 days from the diagnosis to plasma administration, oxygen dependency was prolonged vs. patients with shorter interval (p = 0.006). In conclusion, the combination of inhibition of viral replication with passive immunization was proved to be efficient and safe. Our results suggest the clear benefit of early, combined administration of remdesivir and CP to avoid protracted COVID-19 disease among patients with HMs and B-cell lymphopenia.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk COVID-19 SARS-CoV-2 Convalescent plasma treatment Remdesivir Hematological malignancies Immunodeficiency
Megjelenés:	Annals Of Hematology. - 101 : 10 (2022), p. 2337-2345. -
További szerzők:	Pinczés László Imre (1990-) (általános orvos) Páyer Edit (1982-) Farkas Katalin Ujfalusi Szilvia (1990-) (belgyógyász) Diószegi Ágnes (1987-) (belgyógyász) Sik Máté (1991-) (általános orvos) Simon Zsófia (1977-) (belgyógyász, haematológus) Nagy Gergely György (1976-) (orvos) Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: